HLS Therapeutics Net Loss History

HLS Stock  CAD 4.40  0.11  2.56%   
The latest Net Loss for HLS Therapeutics is -18.6 M, from -17.7 M the year before. Multi-year data shows Net Loss firming for HLS Therapeutics'. Net Loss is the net income that remains after preferred dividends have been deducted, available to common shareholders. Complete Financial Overview
 
Net Loss  
 First Reported
2018-06-30
 Previous Quarter
-2.7 M
 Current Value
-3.9 M
 Quarterly Volatility
4.2 M
Macro event markers
 
Covid
 
Interest Hikes
HLS Therapeutics's Net Loss sits within a range defined by its operating history and sector positioning.

Latest HLS Therapeutics' Net Loss Growth Pattern

Plotted below is HLS Therapeutics' Net Loss, tracking 11 years of reported values. The latest annual change of 4.76% continues a firming multi-year pattern. Peaks and troughs in HLS Therapeutics' Net Loss highlight where the most significant shifts occurred.
Net Loss10 Years Trend
Slightly volatile
   Net Income Applicable To Common Shares   
       Timeline  

Net Loss Trend Statistics

Arithmetic Mean-12,464,641
Coefficient Of Variation-75.10
Mean Deviation 8,247,067
Median-14,893,000
Standard Deviation 9,360,378
Sample Variance87.6T
Range25.7M
R-Value-0.81
Mean Square Error31.6T
R-Squared 0.66
Significance 0.000071
Slope-1,508,021
Total Sum of Squares1401.9T

HLS Therapeutics Net Loss History

2026-18.6 M
2025-17.7 M
2024-19.7 M
2023-27.5 M
2022-23.6 M
2021-13.1 M
2020-15.3 M
2019-19.6 M
2018-24.8 M
2017-6.1 M
2016-14.9 M

Methodology, Assumptions & Data Sources

Here is how HLS Therapeutics's Net Loss has changed over time. Year-over-year changes are the easiest way to spot turning points.

The analytics block for HLS Therapeutics relies on periodic company reporting and market reference feeds, with quality checks and normalization applied before rendering. Timing can vary by data vendor. This section presents reference data and historical patterns only and does not constitute an investment recommendation or advice.

This content is curated and reviewed by:

Raphi Shpitalnik - Junior Member of Macroaxis Editorial Board
Last reviewed on March 9th, 2026